Oura wants $16bn for a $399 ring and a subscription line nobody has seen

A large secondary changes who is on which side of the trade. Existing shareholders are expected to sell a major chunk of the offering ^[2], so public buyers would be taking stock from holders who can read the membership file. That file is the one thing outsiders do not have: Oura has never published revenue or membership numbers, and they arrive with the S-1 ^[7].

At more than $16bn, the price implies a subscription business rather than a hardware one. The Ring 5 sells at $399 with a subscription for the analysis ^[13], and The Next Web's reading is that recurring software income is the whole difference between this valuation and a hardware multiple ^[19]. Against the $10.9bn mark from last September ^[3], the ask is roughly 47 percent higher a year on ^[16], while the raise itself is under a fifth of the implied cap ^[17]. Nothing public says whether the recurring line moved at that rate.

The form-factor case holds up on mechanism. Sleep, recovery and readiness are metrics that need the device on the body overnight, which is when a wrist wearable tends to be on its charger ^[21]; a ring has no screen to check and a battery measured in days rather than hours ^[20]. The Next Web dates the category's gains against the Apple Watch to the past two years ^[22]. That is an advantage of purpose over generality, and it is also the kind that copies. Samsung shipped the Galaxy Ring two years ago ^[8], and Oura is suing the rival ring maker Ultrahuman, litigation that The Next Web reads as a proxy for how cheap the category has become to enter ^[14].

Two costs sit under the multiple that pure software does not carry. Rings ship in a range of fixed sizes and cannot be adjusted after purchase, which makes sizing kits and returns a per-unit line that grows with volume ^[15]. And the upgrade most likely to justify a clinical-grade price is the one Oura has avoided on purpose: it sells wellness insight rather than diagnosis, and moving toward diagnosis pulls it into device regulation ^[11].

The nearest subscription rival is priced at $10.1bn by The Next Web's count ^[9] and at $10bn as of March by TechCrunch's, after Whoop added hormone tracking and blood-panel testing ^[10]. Either way, Oura is asking about 1.6 times its closest competitor's private mark ^[18]. That is the gap the prospectus has to explain, and the only material that can explain it is retention.

Worth noting where the work stays and where the money is being raised. Oura employs more than 900 people, its manufacturing and research remain in Finland, and the exchange it wants is in the United States ^[12]. It told the market in May that it had filed confidentially ^[5].